Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;4(6 Pt 1):101755.
doi: 10.1016/j.jacadv.2025.101755. Epub 2025 May 3.

Echocardiographic Tissue Characterization Using Radiomics in Patients With Transthyretin-Related Cardiac Amyloidosis

Affiliations

Echocardiographic Tissue Characterization Using Radiomics in Patients With Transthyretin-Related Cardiac Amyloidosis

Sara Mori et al. JACC Adv. 2025 Jun.

Abstract

Background: Transthyretin-related cardiac amyloidosis (ATTR-CA) is often diagnosed at an advanced stage. Emerging evidence suggests that radiomics applied to echocardiographic images (ie, ultrasonomics) can detect early myocardial texture changes in ATTR-CA.

Objectives: This study aimed to develop a radiomic model for characterizing ATTR-infiltrated myocardium via echocardiography.

Methods: Echocardiographic images in parasternal long-axis and apical 4-chamber views from ATTR-CA and control patients were collected across 4 Italian centers. A region of interest (ROI) within the interventricular septum was delineated. Ninety-four radiomic features were extracted and classified into 2 categories for analysis, based on whether they were ROI-dependent or independent. Five logistic regression models analyzed data from 3 centers (229 ATTR-CA, 224 controls) to assess diagnostic accuracy and area under the curve (AUC) of different sets of radiomic features, with external validation conducted on patients from a fourth center (32 ATTR-CA, 32 controls).

Results: Models analyzing the entire ROI using both ROI-dependent and ROI-independent features demonstrated high cross-validated accuracies (93%-95%) and AUC values (0.97-0.99). Using a fixed-size 0.5 × 0.5 cm ROI, these values decreased to 85% and 0.91, respectively, highlighting previous models' dependence on ROI size. The fifth model used 73 ROI-independent features on the entire ROI and demonstrated significantly better accuracy and AUC (92% and 0.97, respectively, P < 0.001), confirmed in the external validation cohort (87% and 0.95, respectively). Removing the least informative features slightly improved the model, achieving 90% accuracy and 0.95 precision.

Conclusions: This study showcases ultrasonomics potential to differentiate ATTR-CA and control patients by capturing disease-specific textural features independent of ROI dimensions.

Keywords: echocardiography; radiomic; texture; transthyretin cardiac amyloidosis.

PubMed Disclaimer

Conflict of interest statement

Funding support and author disclosures Dr Canepa has received speaker and advisor fees from Akcea Therapeutics, Alnylam, AstraZeneca, Boehringer Ingelheim, Boston Scientific, Novartis, Pfizer, Sanofi, and Sanofi Genzyme, and 2 investigator-initiated grants from Pfizer (outside the submitted work). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

None
Graphical abstract
Central Illustration
Central Illustration
Echocardiographic Tissue Characterization Using Radiomics in Patients With Transthyretin-Related Cardiac Amyloidosis (A) Frame extraction and annotation were manually performed by an expert clinical cardiologist, delineating the ROI within IVS with a perimeter that varied according to IVS size. A variable-sized mask was drawn within the left ventricular cavity to provide a brightness reference for grayscale normalization. (B) Radiomic features were divided into 2 classes: shape features (such as ROI area or perimeter) and texture features, which were further divided into ROI-dependent features, whose values vary based on ROI dimension, and ROI-independent features, whose values remain constant regardless of ROI size. (C) Logistic regression models were built to classify control vs ATTR-CA, using different subsets of radiomic features as independent variables. Model performance was assessed via leave-one-out cross-validation. Ranking of radiomic features was computed based on regression coefficients. (D) The best ROI-independent predictive model was selected for external validation after following the same frame extraction and annotation process shown in panel (A). 4CH = 4-chamber; ATTR-CA = transthyretin cardiac amyloidosis; GLCM = gray level co-occurrence matrix; GLRLM = gray level run length matrix; IVS = interventricular septum; PLAX = parasternal long axis; ROI = region of interest.
Figure 1
Figure 1
Top 10 Discriminative Features Logistic regression coefficients of the 10 most discriminative features from model #1 (including all 94 texture and shape features, upper section) and from model #5 (including 73 ROI-independent texture features, lower section) in both the 4CH and PLAX views are shown. Positive coefficients indicate higher values of the corresponding feature in the ATTR-CA group, while negative coefficients indicate higher values in the control group. Feature categories (listed and explained in detail in Supplemental Table 2) are color-coded, and ROI-dependent features are marked with a star. 4CH = 4-chamber; ATTR-CA = transthyretin cardiac amyloidosis; PLAX = parasternal long axis; ROI = region of interest.

References

    1. Garcia-Pavia P., Rapezzi C., Adler Y., et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on myocardial and pericardial diseases. Eur Heart J. 2021;42(16):1554–1568. doi: 10.1093/eurheartj/ehab072. - DOI - PMC - PubMed
    1. Merlo M., Pagura L., Porcari A., et al. Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from phase 2 of the AC-TIVE study, an Italian nationwide survey. Eur J Heart Fail. 2022;24(8):1377–1386. doi: 10.1002/ejhf.2504. - DOI - PubMed
    1. Ioannou A., Patel R.K., Razvi Y., et al. Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation. 2022;146(22):1657–1670. doi: 10.1161/CIRCULATIONAHA.122.060852. - DOI - PMC - PubMed
    1. Gillmore J.D., Maurer M.S., Falk R.H., et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–2412. doi: 10.1161/CIRCULATIONAHA.116.021612. - DOI - PubMed
    1. Tomasoni D., Bonfioli G.B., Aimo A., et al. Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials. Front Cardiovasc Med. 2023;10 doi: 10.3389/fcvm.2023.1154594. - DOI - PMC - PubMed